50% Improvement: Should Treatment Response Go Beyond Symptom Improvement When Evaluating the Treatment of Depression?

References (29)

1. US Food and Drug Administration, Center for Biologics Evaluations and Research. Guidance for Industry: Providing clinical evidence of effectiveness for human drugs and biological products. FDA website. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-clinical-evidence-effectiveness-human-drug-and-biological-products. May 1998.
2. US Food and Drug Administration. Major depressive disorder: developing drugs for treatment. Guidance for industry Docket No. FDA-2018-D-1919. FDA website. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/major-depressive-disorder-developing-drugs-treatment. 2018:28851–28853.
3. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–758. PubMed CrossRef
4. Cuijpers P, Noma H, Karyotaki E, et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19(1):92–107. PubMed CrossRef
5. Iovieno N, Papakostas GI. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. J Clin Psychiatry. 2012;73(10):1300–1306. PubMed CrossRef
6. Rutherford BR, Cooper TM, Persaud A, et al. Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout. J Clin Psychiatry. 2013;74(7):703–715. PubMed CrossRef
7. Zimmerman M, McGlinchey JB, Posternak MA, et al. How should remission from depression be defined? the depressed patient’s perspective. Am J Psychiatry. 2006;163(1):148–150. PubMed CrossRef
8. Demyttenaere K, Donneau AF, Albert A, et al. What is important in being cured from depression? discordance between physicians and patients (1). J Affect Disord. 2015;174:390–396. PubMed CrossRef
9. Baune BT, Christensen MC. Differences in perceptions of major depressive disorder symptoms and treatment priorities between patients and health care providers across the acute, post-acute, and remission phases of depression. Front Psychiatry. 2019;10:335. PubMed CrossRef
10. Holtforth MG, Wyss T, Schulte D, et al. Some like it specific: the difference between treatment goals of anxious and depressed patients. Psychol Psychother. 2009;82(Pt 3):279–290. PubMed CrossRef
11. Ramnerö J, Jansson B. Treatment goals and their attainment: a structured approach to assessment and evaluation. Cogn Behav Ther. 2016;9:E2. CrossRef
12. Uebelacker LA, Battle CL, Friedman MA, et al. The importance of interpersonal treatment goals for depressed inpatients. J Nerv Ment Dis. 2008;196(3):217–222. PubMed CrossRef
13. Zimmerman M, Martinez JH, Attiullah N, et al. A new type of scale for determining remission from depression: the Remission from Depression Questionnaire. J Psychiatr Res. 2013;47(1):78–82. PubMed CrossRef
14. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. PubMed CrossRef
15. Zimmerman M, Galione JN, Attiullah N, et al. Depressed patients’ perspectives of two measures of outcome: The Quick Inventory of Depressive Symptomatology (QIDS) and the Remission from Depression Questionnaire (RDQ). Ann Clin Psychiatry. 2011;23(3):208–212. PubMed
16. Zimmerman M, Martinez JH, Attiullah N, et al. The remission from depression questionnaire as an outcome measure in the treatment of depression. Depress Anxiety. 2014;31(6):533–538. PubMed CrossRef
17. Jones R, Yates WR, Williams S, et al. Outcome for adjustment disorder with depressed mood: comparison with other mood disorders. J Affect Disord. 1999;55(1):55–61. PubMed CrossRef
18. First MB, Spitzer RL, Williams JBW, et al. Structured Clinical Interview for DSM-IV (SCID). Washington, D.C.: American Psychiatric Association; 1997.
19. Pfohl B, Blum N, Zimmerman M. Structured Interview for DSM-IV Personality. Washington, DC: American Psychiatric Press, Inc.; 1997.
20. Gelenberg AJ, Freeman MP, Markowitz JC, et al. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Washington, DC: American Psychiatric Association; 2010.
21. Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087–1206. PubMed CrossRef
22. Lam RW, McIntosh D, Wang J, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder, Section 1: disease burden and principles of care. Can J Psychiatry. 2016;61(9):510–523. PubMed CrossRef
23. IsHak WW, Greenberg JM, Balayan K, et al. Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry. 2011;19(5):229–239. PubMed CrossRef
24. Morton E, Foxworth P, Dardess P, et al. “Supporting Wellness”: a depression and bipolar support alliance mixed-methods investigation of lived experience perspectives and priorities for mood disorder treatment. J Affect Disord. 2022;299:575–584. PubMed CrossRef
25. Kan K, Jörg F, Buskens E, et al. Patients’ and clinicians’ perspectives on relevant treatment outcomes in depression: qualitative study. BJPsych Open. 2020;6(3):e44. PubMed CrossRef
26. Cuijpers P. Targets and outcomes of psychotherapies for mental disorders: an overview. World Psychiatry. 2019;18(3):276–285. PubMed CrossRef
27. Zimmerman M, Clark HL, Multach MD, et al. Have treatment studies of depression become even less generalizable?: a review of the inclusion and exclusion criteria in placebo controlled antidepressant efficacy trials published during the past 20 years. Mayo Clin Proc. 2015;90(9):1180–1186. PubMed CrossRef
28. Zimmerman M, Chelminski I, McDermut W. Major depressive disorder and Axis I diagnostic comorbidity. J Clin Psychiatry. 2002;63(3):187–193. PubMed CrossRef
29. Herrman H, Patel V, Kieling C, et al. Time for united action on depression: a Lancet–World Psychiatric Association Commission. Lancet. 2022;399(10328):957–1022. PubMed CrossRef